Free Trial

Aadi Bioscience (NASDAQ:AADI) Stock Price Up 1.1% - Here's Why

Aadi Bioscience logo with Medical background

Aadi Bioscience, Inc. (NASDAQ:AADI - Get Free Report)'s share price rose 1.1% during trading on Thursday . The company traded as high as $1.92 and last traded at $1.88. Approximately 25,278 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 253,080 shares. The stock had previously closed at $1.86.

Aadi Bioscience Trading Up 5.9%

The stock has a 50 day simple moving average of $1.81 and a 200 day simple moving average of $2.21. The firm has a market capitalization of $49.15 million, a PE ratio of -0.87 and a beta of 0.68.

Hedge Funds Weigh In On Aadi Bioscience

Several hedge funds have recently made changes to their positions in the business. QVT Financial LP purchased a new position in shares of Aadi Bioscience during the fourth quarter valued at approximately $7,300,000. Acorn Capital Advisors LLC purchased a new position in shares of Aadi Bioscience during the fourth quarter valued at approximately $3,619,000. Ally Bridge Group NY LLC purchased a new position in shares of Aadi Bioscience during the fourth quarter valued at approximately $2,581,000. Geode Capital Management LLC increased its stake in shares of Aadi Bioscience by 4.1% during the fourth quarter. Geode Capital Management LLC now owns 217,294 shares of the company's stock valued at $686,000 after buying an additional 8,546 shares during the period. Finally, Bridgeway Capital Management LLC increased its stake in shares of Aadi Bioscience by 23.7% during the fourth quarter. Bridgeway Capital Management LLC now owns 115,400 shares of the company's stock valued at $364,000 after buying an additional 22,100 shares during the period. 52.08% of the stock is owned by hedge funds and other institutional investors.

About Aadi Bioscience

(Get Free Report)

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.

Featured Articles

Should You Invest $1,000 in Aadi Bioscience Right Now?

Before you consider Aadi Bioscience, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aadi Bioscience wasn't on the list.

While Aadi Bioscience currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

ALERT: Big Tech Earnings – Watch Before Wednesday
ACT FAST! Congress is Dumping these 3 Stocks
3 “Boring” Mega Cap Stocks to Turn Into Pure Profit

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines